BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 7973773)

  • 1. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
    Douay L; Hu C; Giarratana MC; Gorin NC
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
    Grant S; Bhalla K; Arlin Z; Howe CW
    Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals.
    Patchen ML; MacVittie TJ
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):26-32. PubMed ID: 7526469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
    Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
    Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
    Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of amifostine in bone marrow purging.
    Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
    Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
    Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
    Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
    Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment.
    Meagher RC; Rothman SA; Paul P; Koberna P; Willmer C; Baucco PA
    Cancer Res; 1989 Jul; 49(13):3637-41. PubMed ID: 2543500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducing effects of macrophage stimulating protein on the expansion of early hematopoietic progenitor cells in liquid culture.
    Ma LX; Huang YH; Cheng LM; Lei J; Wang QR
    Chin Med J (Engl); 2007 Jul; 120(13):1192-7. PubMed ID: 17637252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
    Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
    Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
    Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
    Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
    Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
    Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
    Giarratana MC; Gorin NC; Douay L
    Nouv Rev Fr Hematol (1978); 1995; 37(2):125-30. PubMed ID: 7644349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging.
    Beran M; Andersson BS; Wang Y; McCredie KB; Farquhar D
    Cancer Res; 1988 Jan; 48(2):339-45. PubMed ID: 3275495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow.
    Slanicka Krieger M; Nissen C; Manz CY; Toksoz D; Lyman SD; Wodnar-Filipowicz A
    Exp Hematol; 1998 May; 26(5):365-73. PubMed ID: 9590652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro response of normal and aplastic anemia bone marrow to mast cell growth factor and in combination with granulocyte-macrophage colony-stimulating factor and interleukin-3.
    Gibson FM; Scopes J; Daly S; Ball SE; Gordon-Smith EC
    Exp Hematol; 1994 Mar; 22(3):302-12. PubMed ID: 8112428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.